VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ILMN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ILMNIllumina, Inc.
$181.10$27.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksILMNFinancials

Illumina, Inc. (ILMN) Financials

27Y historyFree accessUpdated daily

Gross margins have recovered to 66.1% as of 2026Q1, reflecting improved manufacturing efficiencies despite stagnant revenue growth that has fluctuated within a narrow band over the last ten quarters.

ILMN Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Jan'23Jan'22Jan'21Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Sales/Revenue4.39B4.34B4.37B4.5B4.58B4.53B3.24B3.54B3.33B2.75B2.4B2.22B1.86B1.42B1.15B1.06B902.74M666.32M573.23M366.8M184.59M73.5M50.58M28.04M10.04M2.49M1.31M474.03K
Revenue Growth %1.25%-0.78%-2.93%-1.75%1.28%39.73%-8.58%6.3%21.11%14.74%8.05%19.25%30.97%23.74%8.81%16.93%35.48%16.24%56.28%98.71%151.13%45.31%80.43%179.23%303.86%89.9%176.17%-
Cost of Goods Sold1.44B1.45B1.51B1.76B1.61B1.37B1.04B1.08B1.03B926M732M671M563.65M509.29M374.99M346.44M301.2M205.77M205.62M132.44M59.34M23.18M13.26M10.04M3.54M557K-398K-96.37K
COGS % of Revenue-33.31%34.56%39.08%35.17%30.31%31.99%30.37%30.99%33.65%30.52%30.23%30.28%35.84%32.65%32.82%33.37%30.88%35.87%36.11%32.15%31.54%26.21%35.8%35.22%22.41%-30.4%-20.33%
Gross Profit2.95B2.89B2.86B2.74B2.97B3.15B2.2B2.47B2.3B1.83B1.67B1.55B1.3B911.89M773.53M709.1M601.54M460.56M367.6M234.36M125.24M50.32M37.32M18M6.5M1.93M1.71M570.39K
Gross Margin %67.14%66.69%65.44%60.92%64.83%69.69%68.01%69.63%69.01%66.35%69.46%69.78%69.72%64.16%67.35%67.18%66.63%69.12%64.13%63.89%67.85%68.46%73.79%64.2%64.78%77.59%130.39%120.33%
Gross Profit Growth %-1.12%4.26%-7.67%-5.77%43.17%-10.7%7.26%25.96%9.6%7.55%19.36%42.31%17.89%9.09%17.88%30.61%25.29%56.85%87.13%148.89%34.82%107.38%176.72%237.17%13.01%199.27%-
Operating Expenses2.03B2.03B3.69B3.81B7.15B3.28B1.62B1.48B1.42B1.22B1.08B936M783M777.78M572.78M509.64M389.89M334.96M287.14M535.57M87.43M71.77M42.84M44.62M48.36M32.25M24.94M6.49M
OpEx % of Revenue-46.77%84.49%84.66%156%72.4%50.11%41.83%42.51%44.33%44.99%42.17%42.07%54.73%49.87%48.28%43.19%50.27%50.09%146.01%47.37%97.64%84.69%159.16%481.66%1297.18%1905.26%1368.87%
Selling, General & Admin1.08B1.08B1.09B1.61B1.3B2.09B941M835M794M674M584M516M466.28M381.04M285.99M261.84M220.45M176.34M148.01M101.26M54.06M27.97M25.08M18.9M9.1M5.66M4.19M1.35M
SG&A % of Revenue-24.85%24.98%35.79%28.29%46.22%29.05%23.57%23.82%24.49%24.35%23.25%25.05%26.81%24.9%24.81%24.42%26.46%25.82%27.61%29.29%38.06%49.58%67.41%90.63%227.8%320.29%284.56%
Research & Development949M951M1.17B1.35B1.32B1.19B682M647M623M546M504.42M401.53M388.06M276.74M231.03M196.91M177.95M140.62M99.96M73.94M33.37M27.73M21.11M22.51M26.85M20.73M13.55M4.09M
R&D % of Revenue-21.92%26.74%30.06%28.82%26.18%21.06%18.26%18.69%19.84%21.03%18.09%20.85%19.47%20.12%18.66%19.71%21.1%17.44%20.16%18.08%37.72%41.74%80.3%267.41%834.07%1035.39%861.92%
Other Operating Expenses001.43B847M4.53B00000-9M19M-71.34M120M55.76M50.88M-8.52M18M39.17M360.37M016.07M-3.36M3.21M12.41M5.85M7.2M1.05M
Operating Income919M864M-833M-1.07B-4.18B-123M580M985M883M606M587M613M514.71M134.11M200.75M199.46M211.65M125.6M80.46M-301.21M37.81M-21.45M-5.51M-26.62M-41.85M-30.32M-23.23M-5.92M
Operating Margin %20.93%19.92%-19.05%-23.73%-91.16%-2.72%17.91%27.8%26.49%22.02%24.47%27.62%27.65%9.44%17.48%18.9%23.45%18.85%14.04%-82.12%20.48%-29.18%-10.9%-94.96%-416.88%-1219.59%-1774.87%-1248.54%
Operating Income Growth %-203.72%22.08%74.42%-3297.56%-121.21%-41.12%11.55%45.71%3.24%-4.24%19.1%283.81%-33.2%0.65%-5.76%68.52%56.1%126.71%-896.6%276.3%-289.03%79.29%36.39%-38.05%-30.49%-292.59%-
EBITDA1.12B1.13B-479M-637M-3.79B128M767M1.17B1.06B762M728M740M627.28M232.03M266.07M268.65M253.66M156.78M108.18M-285.39M43.52M-17.45M-515K-19.19M-32.35M-22.56M-16.04M-4.86M
EBITDA Margin %25.53%26.14%-10.96%-14.14%-82.57%2.83%23.68%33.11%31.86%27.69%30.35%33.34%33.7%16.33%23.17%25.45%28.1%23.53%18.87%-77.8%23.58%-23.74%-1.02%-68.45%-322.26%-907.32%-1225.26%-1026.15%
EBITDA Growth %674.87%336.74%24.8%83.17%-3057.03%-83.31%-34.61%10.45%39.37%4.67%-1.62%17.97%170.34%-12.79%-0.96%5.91%61.79%44.93%137.91%-755.76%349.4%-3288.35%97.32%40.69%-43.44%-40.62%-229.75%-
D&A (Non-Cash Add-back)202M270M354M432M394M251M187M188M179M156M141M127M112.57M97.92M65.32M69.19M42.01M31.18M27.72M15.82M5.71M4M5M7.43M9.5M7.76M7.2M1.05M
EBIT919M864M-1.08B-1.04B-4.31B945M905M1.17B951M1.08B594M626M490.49M199M260.39M167.84M209.98M137.84M94.9M2.19M37.81M-5.65M-5.51M-26.62M-41.85M-30.32M-23.23M-5.92M
Net Interest Income-47M-61M-54M-19M-15M-61M-8M23M-13M-18M-23M-38M-37.83M-34.8M-21.57M-27.74M-16.22M-12.69M-9.69M-632.88M0-14.4M01.06M-4.25M000
Interest Income29M40M46M58M11M041M75M44M19M10M5M3.9M4.89M16.21M7.05M8.38M11.03M12.52M16.03M01.4M01.82M3.81M000
Interest Expense76M101M100M77M26M61M49M52M57M37M33M43M41.73M39.69M37.78M34.79M24.6M23.72M22.21M000000000
Other Income/Expense142M222M-346M-48M-157M1.01B276M133M11M437M-26M-30M-65.95M25.21M21.86M-66.42M-26.27M-11.47M-7.77M12.43M4.81M21.45M5.51M26.62M41.85M30.32M23.23M5.92M
Pretax Income1.06B1.09B-1.18B-1.12B-4.34B884M856M1.12B894M1.04B561M583M448.76M159.31M222.61M133.04M185.38M114.13M72.69M-288.79M42.62M0000000
Pretax Margin %24.16%25.03%-26.97%-24.8%-94.59%19.53%26.43%31.56%26.82%37.9%23.39%26.26%24.11%11.21%19.38%12.6%20.54%17.13%12.68%-78.73%23.09%-------
Income Tax208M236M44M44M68M122M200M128M112M365M133M125M95.41M34.01M71.35M46.42M60.49M41.84M33.27M-10.43M2.65M0000000
Effective Tax Rate %19.6%21.73%-3.73%-3.94%-1.57%13.8%23.36%11.45%12.53%35%23.71%21.44%21.26%21.35%32.05%34.89%32.63%36.67%45.77%3.61%6.22%-------
Net Income853M850M-1.22B-1.16B-4.4B762M656M1B826M726M462.65M461.56M353.35M125.31M151.25M86.63M124.89M72.28M50.48M-278.36M39.97M-20.87M-6.22M-27.06M-40.33M-24.82M-18.61M-5.52M
Net Margin %19.43%19.59%-27.97%-25.78%-96.07%16.84%20.25%28.28%24.78%26.38%19.29%20.79%18.98%8.82%13.17%8.21%13.83%10.85%8.81%-75.89%21.65%-28.4%-12.31%-96.53%-401.7%-998.51%-1421.31%-1164%
Net Income Growth %188.39%169.5%-5.34%73.64%-677.95%16.16%-34.53%21.31%13.77%56.92%0.24%30.62%181.99%-17.15%74.6%-30.64%72.79%43.2%118.13%-796.45%291.47%-235.33%77%32.9%-62.47%-33.41%-237.22%-
Net Income (Continuing)853M850M-1.22B-1.16B-4.4B762M656M990M782M678M428M458M353.35M125.31M151.25M86.63M124.89M72.28M39.42M-278.36M39.97M-20.87M-6.22M-27.06M-40.33M-24.82M-18.61M-5.52M
Discontinued Operations0000000000000000000000000000
Minority Interest0000000087M220M73.01M32.55M0000000000000000
EPS (Diluted)5.545.45-7.69-7.35-28.055.054.436.725.544.913.133.102.370.901.130.620.870.530.38-2.570.41-0.26-0.09-0.42-0.65-0.42-0.33-1.96
EPS Growth %190.33%170.87%-4.63%73.8%-655.45%14%-34.08%21.3%12.83%56.87%0.97%30.8%163.33%-20.35%82.26%-28.74%64.15%39.47%114.79%-726.83%257.69%-199.54%79.33%35.38%-54.76%-27.27%83.16%-
EPS (Basic)-5.48-7.69-7.35-28.055.084.466.825.624.973.153.182.611.001.230.701.010.590.43-2.570.45-0.26-0.09-0.42-0.65-0.42-0.33-1.96
Diluted Shares Outstanding154M156M159M158M157M151M148M149M149M148M148M149M148.98M139.94M133.69M138.94M143.43M137.1M133.61M108.31M97.51M80.29M71.69M63.85M61.78M59.5M55.63M2.82M
Basic Shares Outstanding153M155M159M158M157M150M147M147M147M146M147M145M135.55M125.08M123M123.4M123.58M123.15M116.86M108.31M89M80.29M71.69M63.85M61.78M59.5M55.63M2.82M
Dividend Payout Ratio----------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Divestiture execution and competition

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Top Line Growth Remains Stagnant

As reported in recent financial statements, Illumina's revenue growth has fluctuated between a 4.9% contraction and a 5.1% expansion over the last ten quarters, suggesting that the company is struggling to find a consistent growth trajectory following the volatility associated with its recent strategic restructuring efforts.

The revenue profile appears to be heavily influenced by cyclical capital equipment cycles and the ongoing transition to the NovaSeq X platform. Investors should monitor whether the current low-single-digit growth represents a permanent shift toward a mature utility model or a temporary lull before a new cycle of clinical adoption.

Gross Margin Recovery Underway

Based on the provided income statement data, gross margins have demonstrated a notable recovery from a low of 60.1% in 2023Q4 to 66.1% in 2026Q1, indicating that the company is successfully navigating the manufacturing complexities associated with its latest generation of high-throughput sequencing technology.

This expansion suggests that the company is regaining pricing power on its consumable stream, which remains the primary engine of profitability. However, the sustainability of these margins warrants further investigation, particularly as competitive pressure from lower-cost sequencing alternatives continues to mount in the clinical diagnostic space.

Operating Efficiency Shows Recent Improvement

According to the latest quarterly filings, Illumina has significantly reduced its SG&A expenses from a peak of $485 million in 2023Q4 to $272 million in 2026Q1, reflecting a concerted effort by management to streamline operations and improve operating leverage following the conclusion of the GRAIL divestiture process.

The reduction in overhead appears to be a critical component of the company's path back to consistent profitability. Analysts should evaluate whether this leaner cost structure is sustainable or if it may eventually constrain the R&D investment necessary to defend the company's technological moat against emerging long-read competitors.

Structural Risks to Long-term Profitability

While recent margins appear to be stabilizing, the historical volatility in net income, which swung from a $2 billion loss in 2024Q2 to a $705 million profit in 2024Q3, suggests that the company's bottom line remains highly susceptible to non-operating items and significant one-time restructuring charges.

Short-sellers may focus on the potential for further margin compression if the company is forced to lower prices to maintain its installed base against aggressive new entrants. The reliance on high-throughput consumables may also be vulnerable if clinical labs prioritize cost-per-report over the raw throughput capabilities that define Illumina's current competitive advantage.

ILMN — Frequently Asked Questions

Quick answers to the most common questions about buying ILMN stock.

What was Illumina, Inc.'s (ILMN) revenue in 2025?

For fiscal year 2025, Illumina, Inc. (ILMN) reported total revenue of $4.34B. This represents a 915039.7% increase compared to $0.5M in 1999.

Is Illumina, Inc. (ILMN) profitable?

Illumina, Inc. (ILMN) is profitable, generating $850.0M in net income for the fiscal year ending 2025 with a net profit margin of 19.6%.

What is Illumina, Inc.'s operating profit margin?

Illumina, Inc. (ILMN) reported an operating income of $864.0M, resulting in an operating profit margin of 19.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Illumina, Inc.'s gross profit and gross margin?

Illumina, Inc. (ILMN) generated $2.89B in gross profit for the year, representing a gross profit margin of 66.7%. This demonstrates the company's core pricing power and production efficiency.